Bio‑Synergy introduces DNA‑Epigenetics kit in India through Kynora Life Sciences

⚡ Key Financial Takeaways

Bio‑Synergy's DNA‑Epigenetics Kit measures gene methylation to reflect lifestyle, diet and environmental impacts on gene expression.

The test evaluates more than 300 biological markers and provides customised lifestyle and nutraceutical guidance.

Kynora Life Sciences handles marketing and distribution of the kit across India.

The launch targets a market concerned with metabolic syndrome, which affects roughly 20% of adults in Mumbai.

All DNA data collected from users is kept confidential, according to the company.

💡 Why It Matters

The kit arrives at a time when India faces a rising burden of metabolic disorders, offering a data‑driven approach to preventive health. By translating epigenetic insights into actionable lifestyle advice, the product could influence how consumers manage risk factors for diabetes and heart disease, potentially reducing future healthcare costs.

New preventive‑health offering for Indian consumers UK health‑science brand Bio‑Synergy has entered the Indian preventive‑health space with its DNA‑Epigenetics Kit. The product is being marketed and distributed by Kynora Life Sciences, marking the company’s first major consumer‑facing launch in the country.

How the kit works Unlike traditional genetic tests that focus solely on DNA sequence, the kit evaluates epigenetic methylation patterns—chemical tags that indicate how external factors such as diet, lifestyle and pollution influence gene activity. The analysis covers over 300 biomarkers, ranging from metabolic indicators to markers of biological ageing. Based on the results, users receive personalised recommendations on diet, exercise and nutraceutical supplements designed to improve metabolic health.

Rationale behind the launch India is witnessing a surge in lifestyle‑related conditions. Bio‑Synergy cites studies showing that about one in five adults in Mumbai exhibit signs of metabolic syndrome, a cluster of risk factors for diabetes and cardiovascular disease. By offering insights into how everyday choices affect gene expression, the kit aims to empower individuals to intervene early.

> “DNA and epigenetics can help people understand their unique biology and make smarter, more personalised choices for a healthier future,” said **Daniel Herman**, founder of Bio‑Synergy UK.

Former NASA scientist **Katherine Rahill**, chief scientific officer at Bio‑Synergy, highlighted that the same epigenetic monitoring principles used for astronauts are now being applied to the general public, enabling early detection of biological changes before they become chronic issues.

Data privacy and market positioning Bio‑Synergy assures that all DNA information collected from users is stored securely and remains confidential. The company positions the kit as a tool for consumers seeking deeper insight into how their habits influence long‑term health, energy levels and ageing.

Looking ahead Having entered India in September 2026 with this platform, Bio‑Synergy plans to expand its product portfolio and may explore collaborations with healthcare providers and wellness platforms to broaden reach.

--- *The information above is based on the company’s announcement and does not constitute medical advice.*

🏛️ Background & Context

Preventive health and personalised wellness are growing segments in India, driven by increasing awareness of lifestyle diseases and greater disposable income among urban consumers. Epigenetic testing, once limited to research and specialised clinical settings, is now being commercialised for the mass market, reflecting broader trends in consumer genomics.

👁️ What To Watch Next

Watch for regulatory responses from Indian health authorities regarding direct‑to‑consumer epigenetic testing, as well as any partnerships Bio‑Synergy may form with hospitals, insurers or digital health platforms. Consumer uptake data and any emerging clinical studies on the kit’s effectiveness will also be key indicators of market impact.